Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.37
NEPT's Cash-to-Debt is ranked lower than
88% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. NEPT: 0.37 )
Ranked among companies with meaningful Cash-to-Debt only.
NEPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.77 Max: No Debt
Current: 0.37
Equity-to-Asset 0.59
NEPT's Equity-to-Asset is ranked lower than
55% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. NEPT: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
NEPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.55 Max: 0.83
Current: 0.59
-0.42
0.83
Interest Coverage 1.33
NEPT's Interest Coverage is ranked lower than
98% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NEPT: 1.33 )
Ranked among companies with meaningful Interest Coverage only.
NEPT' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.33
Current: 1.33
0
1.33
Piotroski F-Score: 4
Altman Z-Score: 0.96
Beneish M-Score: 2.45
WACC vs ROIC
4.54%
6.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 6.95
NEPT's Operating Margin % is ranked higher than
72% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. NEPT: 6.95 )
Ranked among companies with meaningful Operating Margin % only.
NEPT' s Operating Margin % Range Over the Past 10 Years
Min: -262.75  Med: -35.28 Max: 6.95
Current: 6.95
-262.75
6.95
Net Margin % 13.96
NEPT's Net Margin % is ranked higher than
83% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. NEPT: 13.96 )
Ranked among companies with meaningful Net Margin % only.
NEPT' s Net Margin % Range Over the Past 10 Years
Min: -185.54  Med: -32.98 Max: 13.96
Current: 13.96
-185.54
13.96
ROE % 11.54
NEPT's ROE % is ranked higher than
84% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. NEPT: 11.54 )
Ranked among companies with meaningful ROE % only.
NEPT' s ROE % Range Over the Past 10 Years
Min: -596.63  Med: -35.71 Max: 11.54
Current: 11.54
-596.63
11.54
ROA % 6.28
NEPT's ROA % is ranked higher than
84% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. NEPT: 6.28 )
Ranked among companies with meaningful ROA % only.
NEPT' s ROA % Range Over the Past 10 Years
Min: -34.21  Med: -15.56 Max: 6.28
Current: 6.28
-34.21
6.28
ROC (Joel Greenblatt) % 5.28
NEPT's ROC (Joel Greenblatt) % is ranked higher than
74% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. NEPT: 5.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NEPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -80.32  Med: -32.38 Max: 5.28
Current: 5.28
-80.32
5.28
3-Year Revenue Growth Rate -14.60
NEPT's 3-Year Revenue Growth Rate is ranked lower than
69% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NEPT: -14.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NEPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8 Max: 30.5
Current: -14.6
0
30.5
3-Year EBITDA Growth Rate -30.10
NEPT's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NEPT: -30.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NEPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.4  Med: -2.7 Max: 219.3
Current: -30.1
-34.4
219.3
3-Year EPS without NRI Growth Rate -31.40
NEPT's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NEPT: -31.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NEPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 11.3 Max: 200
Current: -31.4
-48.9
200
GuruFocus has detected 3 Warning Signs with Neptune Technologies & Bioressources Inc $NEPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NEPT Guru Trades in

NEPT Guru Trades in

NEPT Guru Trades in

Q2 2015

NEPT Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3741
Compare:NAS:CASI, AMEX:CRMD, NAS:ECYT, NAS:ORMP, AMEX:SYN, AMEX:ATNM, NAS:TTNP, AMEX:XXII, NAS:SNSS, NAS:ARQL, OTCPK:HBPCF, NAS:GTXI, NAS:BCLI, OTCPK:ORGS, NAS:CASC, NAS:IPCI, AMEX:NAVB, OTCPK:PMCB, NAS:VCEL, NAS:CRME » details
Traded in other countries:NEPT.Canada, NTU.Germany,
Neptune Technologies & Bioressources Inc is a biotechnology company. The Company is engaged in the development, manufacture and commercialization of marine‐derived omega‐3 polyunsaturated fatty acids.

Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.

Ratios

vs
industry
vs
history
PE Ratio 14.30
NEPT's PE Ratio is ranked higher than
76% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. NEPT: 14.30 )
Ranked among companies with meaningful PE Ratio only.
NEPT' s PE Ratio Range Over the Past 10 Years
Min: 12.8  Med: 28.73 Max: 965
Current: 14.3
12.8
965
PE Ratio without NRI 14.30
NEPT's PE Ratio without NRI is ranked higher than
77% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. NEPT: 14.30 )
Ranked among companies with meaningful PE Ratio without NRI only.
NEPT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.8  Med: 30.79 Max: 99999999.99
Current: 14.3
12.8
99999999.99
PB Ratio 1.73
NEPT's PB Ratio is ranked higher than
76% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. NEPT: 1.73 )
Ranked among companies with meaningful PB Ratio only.
NEPT' s PB Ratio Range Over the Past 10 Years
Min: 1.55  Med: 5.48 Max: 37.8
Current: 1.73
1.55
37.8
PS Ratio 2.47
NEPT's PS Ratio is ranked higher than
79% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. NEPT: 2.47 )
Ranked among companies with meaningful PS Ratio only.
NEPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 8.33 Max: 33.87
Current: 2.47
1.56
33.87
EV-to-EBIT 40.87
NEPT's EV-to-EBIT is ranked lower than
74% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. NEPT: 40.87 )
Ranked among companies with meaningful EV-to-EBIT only.
NEPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -223.9  Med: -14.7 Max: 1664.6
Current: 40.87
-223.9
1664.6
EV-to-EBITDA 20.64
NEPT's EV-to-EBITDA is ranked lower than
58% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. NEPT: 20.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
NEPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -767.2  Med: -17.3 Max: 714.1
Current: 20.64
-767.2
714.1
PEG Ratio 0.25
NEPT's PEG Ratio is ranked higher than
94% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 1.81 vs. NEPT: 0.25 )
Ranked among companies with meaningful PEG Ratio only.
NEPT' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 6.38 Max: 69.98
Current: 0.25
0
69.98
Current Ratio 2.07
NEPT's Current Ratio is ranked lower than
69% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. NEPT: 2.07 )
Ranked among companies with meaningful Current Ratio only.
NEPT' s Current Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.67 Max: 5.93
Current: 2.07
0.4
5.93
Quick Ratio 1.32
NEPT's Quick Ratio is ranked lower than
75% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. NEPT: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
NEPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.91 Max: 4.87
Current: 1.32
0.2
4.87
Days Inventory 173.27
NEPT's Days Inventory is ranked lower than
65% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. NEPT: 173.27 )
Ranked among companies with meaningful Days Inventory only.
NEPT' s Days Inventory Range Over the Past 10 Years
Min: 58.23  Med: 195.73 Max: 318.25
Current: 173.27
58.23
318.25
Days Sales Outstanding 117.17
NEPT's Days Sales Outstanding is ranked lower than
78% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NEPT: 117.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.93  Med: 115.96 Max: 159.39
Current: 117.17
77.93
159.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
NEPT's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. NEPT: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NEPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.5  Med: -14.8 Max: -6.2
Current: -9.1
-30.5
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 2.46
NEPT's Price-to-Tangible-Book is ranked higher than
74% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NEPT: 2.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NEPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.38  Med: 6.99 Max: 40.59
Current: 2.46
2.38
40.59
Price-to-Median-PS-Value 0.30
NEPT's Price-to-Median-PS-Value is ranked higher than
89% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. NEPT: 0.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NEPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.95 Max: 12
Current: 0.3
0.12
12
Price-to-Graham-Number 1.25
NEPT's Price-to-Graham-Number is ranked higher than
77% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. NEPT: 1.25 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NEPT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.21  Med: 2.2 Max: 8.39
Current: 1.25
1.21
8.39
Earnings Yield (Greenblatt) % 2.40
NEPT's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. NEPT: 2.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NEPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.8 Max: 2.7
Current: 2.4
0.1
2.7

More Statistics

Revenue (TTM) (Mil) $33.92
EPS (TTM) $ 0.07
Beta0.24
Short Percentage of Float2.52%
52-Week Range $0.86 - 1.53
Shares Outstanding (Mil)77.95

Analyst Estimate

Feb17
Revenue (Mil $)
EPS ($) 0.02
EPS without NRI ($) 0.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Acasti Pharma Grants Incentive Stock and Options Feb 24 2017
Neptune to Present at ROTH Capital Partners 29th Annual Growth Stock Conference Feb 22 2017
Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed... Feb 02 2017
Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q3, 2017 By the Numbers :... Jan 18 2017
Neptune Tech posts 3Q profit Jan 12 2017
Neptune Tech posts 3Q profit Jan 12 2017
Acasti Pharma Reports Third Quarter 2017 Financial Results Jan 12 2017
Neptune Announces Record Third Quarter Results Jan 12 2017
Neptune to Hold Conference Call to Discuss Third Quarter Results for the Period Ended November 30,... Jan 04 2017
Neptune to Hold Conference Call to Discuss Third Quarter Results for the Period Ended November 30,... Jan 04 2017
Validity of Neptune’s Patent Upheld by Australian Patent Office / Third Challenge by Enzymotec... Nov 08 2016
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 08 2016
Validity of Neptune's Patent Upheld by Australian Patent Office Nov 07 2016
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 04 2016
Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV Nov 03 2016
Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre Oct 26 2016
Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q2, 2017 By the Numbers :... Oct 18 2016
Neptune Announces Q2 FY 2017 Results Oct 12 2016
Neptune Announces Second Quarter Results Oct 12 2016
Acasti Pharma Reports Second Quarter 2017 Financial Results Oct 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)